Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat.
Systemic administration of haloperidol to rats failed to alter the concentration of dopamine but increased the concentration of 3,4-dihydroxy-phenylacetic acid (DOPAC), the major metabolite of dopamine, in both the striatum and substantia nigra. These haloperidol-induced changes in DOPAC were prevented by an intranigral microinjection of baclofen, a drug which reduces nigrostriatal dopaminergic neuronal activity. It has been proposed that nigrostriatal neurons are regulated, in part, by the activation of autoreceptors in substantia nigra. However, intranigral microinjections of high concentrations of several dopaminergic antagonists failed to mimic the biochemical effects resulting from systemic administration of these drugs; instead, they slightly increased the concentrations of both dopamine and DOPAC in the striatum and decreased dopamine in substantia nigra. Intranigral microinjections of the dopamine agonist, apomorphine, failed to alter the concentration of DOPAC in the striatum, but reduced both dopamine and DOPAC in the nigra. If DOPAC concentrations reflect nigrostriatal dopaminergic neuronal activity, the present results suggest that dopaminergic agonists and antagonists acting in substantia nigra do not exert a major influence on the activity of these neurons.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000613:Aminobutyrates / Q000008:administration & dosage*; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage; D001418:Baclofen / Q000008:administration & dosage*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists; D006220:Haloperidol / Q000008:administration & dosage*; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*
D000613:Aminobutyrates; D018492:Dopamine Antagonists; D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D001418:Baclofen; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine